- Company Presentation Scheduled for Friday, September 9, 2016 at 2:30 PM ET
- Presentation can be viewed via webcast
NEW YORK, Sept. 09, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or the “Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Actinium will be presenting at the BioCentury 23 rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on September 9, 2016 at the Millennium Broadway Hotel & Conference Center in New York, NY.
Presentation Time: 2:30 PM ET Presentation Room: Room 302/303 Breakout: 3:00 – 3:30 PM ET Breakout Room: 301
The Company’s presentation will be webcasted and can be accessed through the following link http://wsw.com/webcast/biocentury3/atnm . The presentation will be archived and available for playback via Actinium’s investor relations page of its website http://ir.actiniumpharma.com/ir-calendar .
Actinium’s executive management will be available for 1-on-1 meetings with conference attendees. To schedule a meeting with management contact Steve O’Loughlin, Vice President, Finance and Corporate Development at soloughlin@actiniumpharma.com or utilize the conference’s meeting system:
https://www.meetmax.com/sched/event_38669/inv...t_id=38669
About BioCentury NewsMakers Conference
NewsMakers presents a hand-picked group of public biotech companies whose corporate and regulatory milestones will drive stock prices. NewsMakers is recognized as the industry's key venue for companies to take their story to Wall Street each Fall. Thus, NewsMakers remains the best opportunity for business development executives and key members of the institutional investment and analyst communities to compare notes and assess the industry landscape.
Last year, more than 500 delegates congregated at NewsMakers , including money managers who controlled more than $480 billion in equity assets, with over $50 billion dedicated to healthcare and $15 billion dedicated to biotech.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. ( www.actiniumpharma.com ) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact: Steve O'Loughlin Vice President, Finance and Corporate Development Actinium Pharmaceuticals, Inc. soloughlin@actiniumpharma.com
